Generate Biomedicines, Inc. Priced its initial public offering of 25 million shares of common stock at $16.00 per share on Thursday, February 26, 2026, the company announced. The offering is expected to generate gross proceeds of $400 million, before accounting for underwriting discounts, commissions, and expenses.
The clinical-stage generative biology company, which is pioneering the use of artificial intelligence in biotechnology and drug development, is slated to begin trading on the Nasdaq Global Select Market under the ticker symbol “GENB” on Friday, February 27, 2026. The offering is expected to officially close on March 2, 2026, contingent upon standard closing conditions, according to a company press release.
Generate Biomedicines has also granted underwriters an option to purchase up to an additional 3,750,000 shares at the initial public offering price, less associated discounts and commissions. Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint lead book-running managers for the offering. Piper Sandler, Guggenheim Securities, and Cantor are acting as book-running managers.
The company, headquartered in Somerville, Massachusetts, focuses on designing AI-engineered protein therapeutics. According to the company, its Generate Platform is designed to be applicable across various therapeutic areas and protein modalities, aiming to address challenges beyond the scope of traditional technologies. Generate currently employs 312 people.
A registration statement related to the securities has been declared effective by the U.S. Securities and Exchange Commission (SEC) on February 26, 2026. Information regarding the offering, including a copy of the final prospectus when available, can be obtained from the underwriting firms: Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, Piper Sandler & Co., Guggenheim Securities, LLC, and Cantor Fitzgerald & Co.
The company’s market capitalization is estimated at $2.04 billion, with recent revenue totaling $31.89 million, representing a 55.9% increase. Generate Biomedicines reported a net loss of $203.15 million, with earnings per share (EPS) at -$1.59. There are currently 127.45 million shares outstanding.
